Climb Bio, Inc. (CLYM)
NASDAQ · Healthcare
$12.22-3.78%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $857.76M
- P/E ratio
- —
- EPS
- —
- Volume
- 837,451
- 52-week high
- —
- 52-week low
- —
- Open
- $12.70
- Day high
- $13.18
- Day low
- $12.14
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$59.85M | -$0.88 |
| 2024 | — | -$73.9M | -$1.53 |
| 2023 | — | -$35.12M | -$1.30 |
| 2022 | — | -$45.24M | -$1.72 |
| 2021 | — | -$47.48M | -$4.24 |
About Climb Bio, Inc.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
- CEO
- Aoife Brennan BCh MMSc
- Employees
- 29
- Country
- US
- IPO date
- Aug 10, 2021
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Climb Bio, Inc.'s stock price today?
- CLYM is trading at $12.22 as of Jul 20, 2026.
- What is Climb Bio, Inc.'s market cap?
- Climb Bio, Inc. (CLYM) has a market capitalization of $857.76M.
- Does Climb Bio, Inc. pay a dividend?
- Climb Bio, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Climb Bio, Inc. in?
- Climb Bio, Inc. operates in the Healthcare sector.